[an error occurred while processing this directive] | [an error occurred while processing this directive]
Research progress in PD-1/PD-L1 monoclonal antibody combined with radiotherapy in treatment of solid tumors
Wang Qianrong,Li Baosheng
School of Medicine and Life Sciences,University of Ji’nan-Shangdong Academy of Medical Sciences,Ji’nan 250022,China (Wang QR); Sixth Department of Radiation Oncology,Shangdong Cancer Hospital Affiliated to Shangdong University,Ji’nan 250117,China (Wang QR,Li BSH)
Abstract D-1/PD-L1 monoclonal antibody combined with radiotherapy enhances anti-tumor immune response and achieves substantial treatment outcomes in preclinical studies of some solid tumors. Therefore, the combination therapy is a promising clinical treatment mode for solid tumors. Extensive studies have focused on the mechanism, timing, fractionation mode, and radiation dose of the combination therapy. This paper reviews the research progress in PD-1/PD-L1 monoclonal antibody combined with radiotherapy for treating solid tumors.
Corresponding Authors:
Li Baosheng,Email:baoshli1963@163.com
Cite this article:
Wang Qianrong,Li Baosheng. Research progress in PD-1/PD-L1 monoclonal antibody combined with radiotherapy in treatment of solid tumors[J]. Chinese Journal of Radiation Oncology, 2016, 25(12): 1375-1378.
Wang Qianrong,Li Baosheng. Research progress in PD-1/PD-L1 monoclonal antibody combined with radiotherapy in treatment of solid tumors[J]. Chinese Journal of Radiation Oncology, 2016, 25(12): 1375-1378.
[1] Frey B,Gaipl US.Radio-immunotherapy:the focused beam expands[J].Lancet Oncol,2015,16(7):742-743.10.1016/S1470-2045(15)00055-8. [2] Tang C,Wang XH,Soh H,et al. Combining radiation and immunotherapy:a new systemic therapy for solid tumors?[J].Cancer Immunol Res,2014,2(9):831-838.10.1158/2326-6066.CIR-14-0069. [3] Corthay A.Does the immune system naturally protect against cancer?[J].Front Immunol,2014,5:197.10.3389/fimmu.2014.00197. [4] Keir ME,Butte MJ,Freeman GJ,et al. PD-1 and its ligands in tolerance and immunity[J].Annu Rev Immunol,2008,26(1):677-704.10.1146/annurev.immunol.26.021607.090331. [5] Hino R,Kabashima K,Kato Y,et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma[J].Cancer,2010,116(7):1757-1766.10.1002/cncr.24899. [6] Boland JM,Kwon ED,Harrington SM,et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung[J].Clin Lung Cancer,2013,14(2):157-163.10.1016/j.cllc.2012.05.006. [7] Lyford-Pike S,Peng SW,Young GD,et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma[J].Cancer Res,2013,73(6):1733-1741.10.1158/0008-5472.CAN-12-2384. [8] Zhang Y,Wang L,Li Y,et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma[J].OncoTargets Ther,2014,7:567-573.10.2147/OTT.S59959. [9] Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12(4):252-264.10.1038/nrc3239. [10] Parker AS,Leibovich BC,Lohse CM,et al. Development and evaluation of BioScore:a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma[J].Cancer,2009,115(10):2092-2103.10.1002/cncr.24263. [11] Hamanishi J,Mandai M,Iwasaki M,et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer[J].Proc Natl Acad Sci U S A,2007,104(9):3360-3365.10.1073/pnas.0611533104. [12] 林城,陈雄,刘静南,等.PD-1/PD-L1信号通路在非小细胞肺癌免疫逃逸及其治疗中的研究进展[J].中国肺癌杂志,2014,17(10):734-740.10.3779/j.issn.1009-3419.2014.10.05. Lin C,Chen X,Liu JN,et al. Research progress of PD-1/PD-L1 signaling pathway in the immune escape of non small cell lung cancer and its treatment[J].Chin J Lung Cancer,2014,17(10):734-740.10.3779/j.issn.1009-3419.2014.10.05. [13] Topalian SL,Drake CG,Pardoll DM.Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity[J].Curr Opin Immunol,2012,24(2):207-212.10.1016/j.coi.2011.12.009. [14] Reits EA,Hodge JW,Herberts CA,et al. Radiation modulates the peptide repertoire,enhances MHC class I expression,and induces successful antitumor immunotherapy[J].J Exp Med,2006,203(5):1259-1271.10.1084/jem.20052494. [15] Gupta A,Probst HC,Vuong V,et al. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation[J].J Immunol,2012,189(2):558-566.10.4049/jimmunol.1200563. [16] Lee YJ,Auh SL,Wang YG,et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells:changing strategies for cancer treatment[J].Blood,2009,114(3):589-595.10.1182/blood-2009-02-206870. [17] Chakraborty M,Abrams SI,Camphausen K,et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy[J].J Immunol,2003,170(12):6338-6347.10.4049/jimmunol.170.12.6338. [18] Teng FF,Kong L,Meng XJ,et al. Radiotherapy combined with immune checkpoint blockade immunotherapy:achievements and challenges[J].Cancer Lett,2015,365(1):23-29.10.1016/j.canlet.2015.05.012. [19] Park SS,Dong H,Liu X,et al. PD-1 Restrains radiotherapy-induced abscopal effect[J].Cancer Immunol Res,2015,3(6):610-619.10.1158/2326-6066.CIR-14-0138. [20] Dovedi SJ,Adlard AL,Grazyna LB,et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade[J].Cancer Res,2014,74(19):5458-5468.10.1158/0008-5472.CAN-14-1258. [21] Kachikwu EL,Iwamoto KS,Liao YP,et al. Radiation enhances regulatory T cell representation[J].Int J Radiat Oncol Biol Phys,2011,81(4):1128-1135.10.1016/j.ijrobp.2010.09.034. [22] Sakaguchi S,Yamaguchi T,Nomura T,et al. Regulatory T cells and immune tolerance[J].Cell,2008,133(5):775-787.10.1016/j.cell.2008.05.009. [23] Sharabi AB,Nirschl CJ,Kochel CM,et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen[J].Cancer Immunol Res,2015,3(4):345-355.10.1158/2326-6066.CIR-14-0196. [24] Deng LF,Liang H,Burnette B,et al. Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression[J].Oncoimmunology,2014,3(4):e28499.10.4161/onci.28499. [25] 于金明,滕菲菲.放疗与免疫治疗联合应用的相关机制及研究进展[J].中国肿瘤临床,2014,41(9):547-550. Yu JM,Teng FF.Mechanism and research progress of combined application of radiotherapy and immunotherapy[J].Chin J Clin Oncol,2014,41(9):547-550. [26] Dewan M Z,Galloway AE,Kawashima N,et al. Fractionated but not single-dose radiotherapy induces an immune-mediated Abscopal effect when combined with anti-CTLA-4 antibody[J].Clin Cancer Res,2009,15(17):5379-5388.10.1158/1078-0432.CCR-09-0265. [27] 秦颂兵.全人源抗PD-L1抗体的筛选及其与放疗联合治疗肿瘤的效果和机制研究[D].苏州:苏州大学,2015. Qin SB.Screening of human anti PD-L1 antibody and its effect and mechanism in combination with radiotherapy combined with radiotherapy[D].Suzhou:Soochow University,2015. [28] Sharabi AB,Lim M,DeWeese TL,et al. Radiation and checkpoint blockade immunotherapy:radiosensitisation and potential mechanisms of synergy[J].Lancet Oncol,2015,16(13):e498-e509.10.1016/S1470-2045(15)00007-8. [29] Verbrugge I,Hagekyriakou J,Sharp LL,et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies[J].Cancer Res,2012,72(13):3163-3174.10.1158/0008-5472.CAN-12-0210. [30] Sibaud V,David I,Lamant L,et al. Acute skin reaction suggestive of pembrolizumab-induced radiosensitization[J].Melanoma Res,2015,25(6):555-558.10.1097/CMR.0000000000000191. [31] Vaughan A,Rao SSD.Radiobiology of stereotactic radiosurgery and stereotactic body radiotherapy[A]//Handbook of Evidence-Based Stereotactic Radiosurgery and Stereotactic Body Radiotherapy[M].Switzerland:Springer International Publishing,2016. [32] Deng LF,Liang H,Burnette B,et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice[J].J Clin Invest,2014,124(2):687-695.10.1172/JCI67313. [33] Zeng J,See AP,Phallen J,et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas[J].Int J Radiat Oncol Biol Phys,2013,86(2):343-349.10.1016/j.ijrobp.2012.12.025. [34] Victor CTS,Rech AJ,Maity A,et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer[J].Nature,2015,520(7547):373-377.10.1038/nature14292. [35] Verbrugge I,Gasparini A,Haynes NM,et al. The curative outcome of radioimmunotherapy in a mouse breast cancer model relies on mTOR signaling[J].Radiat Res,2014,182(2):219-229.10.1667/RR13511.1. [36] Frey B,Rubner Y,Wunderlich R,et al. Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation-implications for cancer therapies[J].Curr Med Chem,2012,19(12):1751-1764.10.2174/092986712800099811. [37] Brahmer JR,Horn L,Antonia SJ,et al. Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1;BMS-936558;ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC)[J].J Clin Oncol,2013,31(15):8030. [38] Teply BA,Lipson EJ.Identification and management of toxicities from immune checkpoint-blocking drugs[J].Oncology,2014,28 Suppl 3:30-38. [39] Kiess AP,Wolchok JD,Barker CA,et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving Ipilimumab:safety profile and efficacy of combined treatment[J].Int J Radiat Oncol Biol Phys,2015,92(2):368-375.10.1016/j.ijrobp.2015.01.004. [40] Kwon ED,Drake CG,Scher HI,et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043):a multicentre,randomised,double-blind,phase 3 trial[J].Lancet Oncol,2014,15(7):700-712.10.1016/S1470-2045(14)70189-5. [41] Crittenden M,Kohrt H,Levy R,et al. Current clinical trials testing combinations of immunotherapy and radiation[J].Semin Radiat Oncol,2015,25(1):54-64.10.1016/j.semradonc.2014.07.003.
2016, Vol. 25 
